GPP
PCRX icon

Great Point Partners’s Pacira BioSciences PCRX Stock Holding History

Great Point Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-300,000
Closed -$14.3M – 42
2017
Q2 		$14.3M Buy
+300,000
New +$13.9M 2.56% 17

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Great Point Partners's PCRX Position: Q3 2017 in Review

Great Point Partners sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 300,000 shares — an estimated $14.3M sold.

Great Point Partners first reported a position in PCRX in Q2 2017 and held it in 1 quarter. The position peaked at $14.3M in Q2 2017. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • Great Point Partners reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • Great Point Partners sold 300,000 Pacira BioSciences shares in Q3 2017, an estimated $14.3M.
  • Great Point Partners first reported a position in Pacira BioSciences in Q2 2017 and held it in 1 quarter.
  • Great Point Partners's Pacira BioSciences position peaked at $14.3M in Q2 2017.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Great Point Partners's 13F filing for Q3 2017, filed 14 Nov 2017.